(PRFX) – Company Press Releases
-
PainReform Announces Closing of $4 Million Public Offering
-
PainReform Announces Pricing of $4 Million Public Offering
-
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
-
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
-
PainReform Provides Year-End Business Update
-
PainReform to Present at the Microcap Conference in Atlantic City
-
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief
-
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
-
PainReform Provides Business Update for the Third Quarter of 2023
-
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
-
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
-
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
-
PainReform Provides Business Update for the Second Quarter of 2023
-
PainReform Regains Compliance with Nasdaq Continued Listing Requirements
-
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement
-
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
-
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
-
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
-
PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
-
PainReform Provides Business Update for the First Quarter of 2023
-
PainReform CEO to Present at Aegis Virtual Conference on May 4th
-
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
-
PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th
-
PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery
-
PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy
-
PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery
-
PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement
-
PainReform Provides Business Update for the Third Quarter of 2022
-
PainReform Provides Further Update on Manufacturing of PRF-110
-
PainReform Provides PRF-110 Manufacturing Update
-
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
PainReform Provides Business Update for the Second Quarter of 2022
-
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
-
PainReform Provides Business Update for the First Quarter of 2022
-
PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th
-
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th
-
PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022
-
PainReform CEO to Participate in the Benzinga All Access Event on December 16th
-
PainReform Provides Business Update for the Third Quarter of 2021
-
PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
-
PainReform Provides Business Update for the Second Quarter of 2021
-
PainReform Provides Business Update for the First Quarter of 2021
-
PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief
-
PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
-
PainReform Announces $6.0 Million Private Placement
-
PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference
-
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
-
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
-
PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors
-
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors
Back to PRFX Stock Lookup
